Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$3.20 USD
+0.06 (1.91%)
Updated Sep 11, 2024 01:47 PM ET
After-Market: $2.98 -0.22 (-6.87%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Lisata Therapeutics, Inc. [LSTA]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Research Collaboration and BOLSTER Completes Enrollment
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MoA Profile Strengthened for Certepetide in CCA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CENDIFOX Study Continues to Make Steady Progress; Pancreatic Cohort Completes Enrollment
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive European Pediatric Regulatory Agreement Brings Certepetide Closer to Market for Pancreatic Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Multiple Data Readouts Set Stage for Next Year; Topline Phase 2b ASCEND Data Expected 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Study of LSTA1 in mPDAC Begins Dosing Patients in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; LSTA1 Momentum Builds Across Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 2a Study of LSTA1 in GBM; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Signal Shows LSTA1 Potential For Complete Response in Advanced Gastroesophageal Tumor
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCEND Completes Enrollment Early; Cohort A Topline Data in 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Momentum Builds For LSTA1 As Clinical Progress Advances Across Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LSTA1 Phase 2 BOLSTER Study Doses First CCA Patient
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Treated in New Phase 2 Trial Aiming to BOLSTER SoC Efficacy in Combination With LSTA1 in Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; LSTA1 Builds Clinical Momentum; Data Readouts Anticipated Throughout 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Enhancements to Phase 2B ASCEND Trial Set Stage for Pivotal Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; LSTA1 Development in Full Swing With Multiple Clinical Trials on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
iLSTA Trial Achieves Lift Off and Finds a Welcome Partner in WARPNINE
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; LSTA1 Clinical Studies Provide Multiple Shots on Goal; Further Trials Expected to Initiate in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; LSTA1 Is the Current Focus For Post- Merger Pipeline; Multiple Key Milestones Expected for 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It?s a Match; Merger Delivers Hybrid Portfolio With Meaningful Near-Term Catalysts; Price Target Adjusted to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
|